LLY

1,010.59

-0.43%↓

JNJ

201.99

-0.22%↓

ABBV

225.56

-1.28%↓

UNH

330.44

-0.79%↓

AZN

90.29

+0.09%↑

LLY

1,010.59

-0.43%↓

JNJ

201.99

-0.22%↓

ABBV

225.56

-1.28%↓

UNH

330.44

-0.79%↓

AZN

90.29

+0.09%↑

LLY

1,010.59

-0.43%↓

JNJ

201.99

-0.22%↓

ABBV

225.56

-1.28%↓

UNH

330.44

-0.79%↓

AZN

90.29

+0.09%↑

LLY

1,010.59

-0.43%↓

JNJ

201.99

-0.22%↓

ABBV

225.56

-1.28%↓

UNH

330.44

-0.79%↓

AZN

90.29

+0.09%↑

LLY

1,010.59

-0.43%↓

JNJ

201.99

-0.22%↓

ABBV

225.56

-1.28%↓

UNH

330.44

-0.79%↓

AZN

90.29

+0.09%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.07 -0.93

Buy Sell

Overview

Share price change

24h

Current

Min

1.07

Max

1.11

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+354.55% upside

Market Stats
By TradingEconomics
Market Cap	-6.9M 119M
Previous open	2
Previous close	1.07

News Sentiment

By Acuity

18%

82%

34 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 gru 2025, 20:41 UTC

Earnings

Major Market Movers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 gru 2025, 18:14 UTC

Acquisitions, Mergers, Takeovers

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 gru 2025, 17:43 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 gru 2025, 17:01 UTC

Earnings

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 gru 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 gru 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4 gru 2025, 21:37 UTC

Earnings

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 gru 2025, 21:36 UTC

Earnings

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 gru 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 gru 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 gru 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 gru 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 gru 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 gru 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 gru 2025, 16:33 UTC

Market Talk

Earnings

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

354.55% upside

12 Months Forecast

Average 5 USD 354.55%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

34 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.